A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Author： Hurvitz Sara   Dalenc Florence   Campone Mario   O’Regan Ruth   Tjan-Heijnen Vivianne   Gligorov Joseph   Llombart Antonio   Jhangiani Haresh   Mirshahidi Hamid   Tan-Chiu Elizabeth   Miao Sara   El-Hashimy Mona   Lincy Jeremie   Taran Tetiana   Soria Jean-Charles   Sahmoud Tarek   André Fabrice  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.141, Iss.3, 2013-10, pp. : 437-446

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

By Iwata Hiroji   Narabayashi Masaru   Ito Yoshinori   Saji Shigehira   Fujiwara Yasuhiro   Usami Shigeyuki   Katsura Koichi   Sasaki Yasutsuna  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 621-628

Springer Publishing Company

Access to resources Recommend Favorite

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

By Sawaki Masataka  

Breast Cancer, Vol. 19, Iss. 3, 2012-07 ,pp. : 253-258

Springer Publishing Company

Access to resources Recommend Favorite